TrialKey leverages advanced machine learning algorithms to simulate trial design and optimise diverse clinical trials, ensuring success across all phases, even for novel conditions. Here’s how TrialKey effectively handles novel conditions and why our model remains robust and reliable.
Dataset Size for Novel Drugs
One might think that the size of the dataset impacts the model’s ability to give positive or negative ratings for novel drugs. However, in the case of TrialKey, execution variables dominate the model’s performance. Execution variables are consistent across trials for novel conditions, making the model’s predictions reliable.
Key Execution Variables
Execution variables, such as protocol design, inclusion and exclusion criteria, primary and secondary endpoints, chosen partners, and countries of operation, play a crucial role. These variables remain consistent and are crucial for the model’s predictions.
Consistent Technology Variables
Similarly, technology variables such as mechanisms, ingestion methods, dosage, and dose frequency are also consistent across novel conditions, further supporting the model’s robustness.
Proven Methodology
Our methodology has been tested and backtested on novel conditions, demonstrating that predictions for novel drugs are as accurate as those for known conditions. This consistency is vital for drugs with available execution variable data.
Machine Learning in Low-Frequency Events
Machine learning’s effectiveness in handling low-frequency events is well-documented in various fields:
- Road Crash Prediction: Predicting crashes on sparsely trafficked roads.
- ICU Admittance Adverse Event Prediction: Using triage data to predict adverse events with only 2% occurrence.
- Drug Discovery: Analyzing mechanisms, compounds, and molecules to accelerate research and reduce risk.
Why Machine Learning Excels at Predicting Low-Frequency Events
- Handling Sparse Data: Detects patterns and makes accurate predictions with limited data.
- Generalization Capability: Performs well on novel or unseen conditions.
- High Dimensionality Handling: Manages and utilizes a large number of variables efficiently.
- Adaptability and Learning: Continuously improves with more data.
- 13 Reduces biases and errors from human judgment.
Machine Learning in Drug Discovery
Machine learning has revolutionized drug discovery, excelling at analyzing mechanisms, compounds, and molecules. It replaces traditional human processes, accelerating research and reducing risk in clinical trials. Techniques like QSAR analysis, hit discoveries, and de novo drug architectures improve decision-making in pharmaceutical data, ensuring accurate outcomes.
TrialKey’s machine learning models are designed to generalize from training data, handle high dimensionality, and adapt to new information, making them highly effective for novel conditions. By leveraging real-world data from over 350,000 trials and comprehensive competitor analysis, TrialKey provides optimal trial design, site selection, patient recruitment, endpoint prediction, and more. This ensures regulatory compliance and enhances the success rates of clinical trials.
Ready to see how TrialKey can optimise your clinical trials?
Book a demo today.
